drugset
drugset / Trial / NCT04800172

The Possible Effects of Roflumilast on Obesity Related Disorders

NCT04800172 ↗

Phase 3 Completed 66 enrolled Tanta University
RandomizedParallel-groupDouble-blindTreatment

Summary

Evaluation of the possible effects of roflumilast on weight, glucose and lipid metabolism, insulin resistance, oxidative stress and inflammatory process in prediabetic obese subjects.

Timeline

Start
2021-05-01
Primary completion
2022-03-31
Completion
2022-03-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Roflumilast Small molecule 500 ug —

Indications

obesity disorder prediabetes syndrome